Scientists from St. Petersburg State University and Togliatti State University (TSU), in collaboration with leading research centers in Germany and the United States, have developed novel molecules that pave the way for next-generation of anticancer drugs with reduced side effects. According to
Gazeta.ru, the research focuses on PROTAC technology, one of the most promising frontiers in modern pharmacology.